About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.
(C) 2024 MINKABU THE INFONOID, Inc.

AFC-HD AMS Life Science Co.,Ltd., Last Fiscal Year Ordinary Profit Revised Upward by 8%

Tue Sep 17, 2024 3:00 pm JST Revision

2927 AFC-HD AMS Life Science Co.,Ltd. 【J-GAAP】

Guidance Update Report

AFC-HD AMS Life Science Co.,Ltd. <2927> [TSE-S] announced a performance revision after the market closed on September 17th (15:00). The consolidated ordinary profit for the fiscal year ending August 2024 has been revised upward by 7.6%, from the previous forecast of 1.78 billion yen to 1.92 billion yen (compared to 1.65 billion yen in the previous period), increasing the growth rate from 8.1% to 16.3%.

Based on the upwardly revised full-year plan announced by the company, our calculation indicates that the March to August period (second half) consolidated ordinary profit has been revised upward by 18.5%, from the previous forecast of 728 million yen to 863 million yen (compared to 946 million yen in the same period of the previous year), and the declining rate is expected to decrease from 23.0% to 8.8%.

Kabutan News

Guidance Update

Second Half Update

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar - Aug, 2024 Prev 13,913 778 728 482 34.3 15 Apr 15, 2024 J-GAAP
Mar - Aug, 2024 New 15,692 871 863 513 36.6 15 Sep 17, 2024 J-GAAP
Revision Rate +12.8% +12.0% +18.5% +6.4% +6.6%

Full Year Update

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Aug, 2024 Prev 28,455 1,801 1,788 1,123 79.9 30 Oct 13, 2023 J-GAAP
Aug, 2024 New 30,234 1,894 1,923 1,154 82.2 30 Sep 17, 2024 J-GAAP
Revision Rate +6.3% +5.2% +7.6% +2.8% +2.9%

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar - Aug, 2023 13,135 958 946 688 49.0 15 Oct 13, 2023 J-GAAP
Mar - Aug, 2024 Guidance 15,692 871 863 513 36.6 15 Sep 17, 2024 J-GAAP
YoY +19.5% -9.1% -8.8% -25.4% -25.4%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Aug, 2022 23,024 1,015 1,343 735 52.3 30 Oct 14, 2022 J-GAAP
Aug, 2023 25,579 1,636 1,654 1,102 78.5 27.50 Oct 13, 2023 J-GAAP
Aug, 2024 Guidance 30,234 1,894 1,923 1,154 82.2 30 Sep 17, 2024 J-GAAP
YoY +18.2% +15.8% +16.3% +4.7% +4.7%

Related Articles